Network pharmacology identifies the mechanisms of action of Jianpi Yanggan Pill in treating diarrhea-predominant irritable bowel syndrome
American Journal of Translational Research · 2026 · 18 (3) · 2507-2521
DOI: 10.62347/gkzd4349 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Translational Research, 2026. Verfasst von Ke Ma und 10 weiteren Autor:innen. Beteiligte Einrichtung: First Clinical Medical College, Nanjing University of Chinese Medicine Nanjing 210023, Jiangsu, China. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
OBJECTIVE: To investigate the molecular mechanisms of Jianpi Yanggan Pill (JPYGP) in treating Diarrhea-predominant irritable bowel syndrome (IBS-D) using an integrated network pharmacology approach combined with experimental validation. METHODS: The chemical constituents of JPYGP were identified by ultra-high performance liquid chromatography-high-resolution mass spectrometry (UHPLC-MS/MS), and bioactive compounds were screened using various databases. Candidate targets was predicted, followed by Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment studies. An IBS-D rat model was established using acetic acid enema combined with restraint stress. The therapeutic potential of JPYGP was further validated through biochemical assays, including Western blotting and enzyme-linked immunosorbent assay (ELISA), to assess the involvement of the C-X-C motif chemokine ligand 8 and extracellular signal-regulated kinase (CXCL8-ERK) signaling pathway. RESULTS: UHPLC-MS/MS analysis identified 2,309 candidate compounds in JPYGP, among which 20 were bioactive. A total of 660 targets were predicted, of which 414 overlapped with IBS-D-related targets. Enrichment analysis highlighted that these targets were mainly involved in inflammatory and MAPK pathways. In a living organism, JPYGP noticeably alleviated diarrhea symptoms and visceral pain, reduced colonic tissue damage, inhibited mast cell activation, and downregulated the expression of CXCL8 and phosphorylated ERK1/2. CONCLUSION: JPYGP exerts therapeutic effects on IBS-D via a multi-component, multi-target mechanism, primarily by suppressing the CXCL8-ERK pathway, thereby attenuating colonic inflammation and visceral hypersensitivity.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- First Clinical Medical College, Nanjing University of Chinese Medicine Nanjing 210023, Jiangsu, China.
- Department of Pi-wei Diseases, The First Affiliated Hospital of Yunnan University of Chinese Medicine Kunming 650021, Yunnan, China.
- Department of Anorectal, Kunming Municipal Hospital of Traditional Chinese Medicine, The Third Affiliated Hospital of Yunnan University of Chinese Medicine Kunming 650011, Yunnan, China.
- Yunnan Institute of Product Quality Supervision and Inspection Kunming 650223, Yunnan, China.
- Department of Pi-wei Diseases, Affiliated Hospital of Traditional Chinese Medicine of Chongqing Three Gorges Medical College Chongqing 404606, China.
- Department of Pi-wei Diseases, Huize County Hospital of Traditional Chinese Medicine Qujing 650021, Yunnan, China.
Zitieren
APA
Ma, K., Hua, X., Li, Z., Zhang, S., Zhu, T., Jin, L., Li, W., Shao, J., Li, X., Wen, W., & Luan, Y. (2026). Network pharmacology identifies the mechanisms of action of Jianpi Yanggan Pill in treating diarrhea-predominant irritable bowel syndrome. American Journal of Translational Research, 18(3), 2507-2521. https://doi.org/10.62347/gkzd4349
Vancouver
Ma K, Hua X, Li Z, Zhang S, Zhu T, Jin L, et al. Network pharmacology identifies the mechanisms of action of Jianpi Yanggan Pill in treating diarrhea-predominant irritable bowel syndrome. American Journal of Translational Research. 2026;18(3):2507-2521. doi:10.62347/gkzd4349
BibTeX
@article{Ma2026,
author = {Ma, Ke and Hua, Xiaokun and Li, Zhipeng and Zhang, Shenghua and Zhu, Ting and Jin, Linxi and Li, Weiping and Shao, Jingran and Li, Xiang and Wen, Weibo and Luan, Yunpeng},
title = {Network pharmacology identifies the mechanisms of action of Jianpi Yanggan Pill in treating diarrhea-predominant irritable bowel syndrome},
journal = {American Journal of Translational Research},
year = {2026},
volume = {18},
number = {3},
pages = {2507--2521},
doi = {10.62347/gkzd4349}
}
EUVIMED